visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH) |
Data: | 2021 |
Resum: | Introduction: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. Expert opinion: Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs. |
Ajuts: | Instituto de Salud Carlos III PI016/0503 Instituto de Salud Carlos III PI14/0063 Instituto de Salud Carlos III PI14/0700 Instituto de Salud Carlos III PI17/0420 Instituto de Salud Carlos III PI17/0498 Instituto de Salud Carlos III PI19/01337 Instituto de Salud Carlos III COVID19 617 Instituto de Salud Carlos III COV20/00070 Instituto de Salud Carlos III RD16/0025/0006 Agencia Estatal de Investigación INT19/00036 Agencia Estatal de Investigación INT20/00031 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014 SGR 250 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017 SGR 948 |
Nota: | Altres ajuts: Gilead Sciences (GLD14/293, GLD17/00299, GLD19/00008) |
Nota: | Altres ajuts: European Regional Development Fund (FEDER) |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | COVID-19 ; SARS-CoV-2 ; Cart ; Remdesivir ; Dexamethasone ; Interferon ; IL-6 antagonists ; LPV/r ; DRV ; TDF ; FTC |
Publicat a: | Expert Opinion on Pharmacotherapy, Vol. 22 Núm. 9 (2021) , p. 1127-1141, ISSN 1744-7666 |
16 p, 945.2 KB |